This requires carefully designed clinical trials that account for commercial dynamics, as well as pre-launch disease education to prime market understanding regarding where new therapies fit in the treatment paradigm
Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement multidisciplinary consensus statement
These pills may not remedy the biggest reason people stop taking GLP-1s: price
Researchers should also distinguish eumelanin from generic darkening
Commercial and employer-based insurance customers also end up on the same cash-pay path Ro doesnt currently bill any insurance directly for GLP-1s, though they do coordinate prior authorization pathways separately
and hence, linked with the pathogenesis of neurodegenerative disorders, including Parkinsons disease 21,22,23